Venetoclax

BNF:
Not listed
Status:
Red
Decision Date:
February 2017
 

Comments

RED: 

  • NICE TA487 - for treating chronic lymphocytic leukaemia. (Decision date - December 2017)
  • NICE TA561 -  with rituximab for previously treated chronic lymphocyctic leukaemia. (Decision date  - March 2019)
  • NICE TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. (Decision date - January 2021) 
  • Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (Decision date - February 2021)
  • NICE TA765 - Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. (Decision date - March 2022)
  • NICE TA787 - Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (Decision date - May 2022)
  • NICE TA796 - Venetoclax for treating chronic lymphocytic leukaemia. NHSE commissioned. (Decision date - July 2022)


NHSE commissioned drug.

 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app